Irinotecan Dosing: Does the CPT in CPT-11 Stand for “Can’t Predict Toxicity”?-Reference-Cited by-同舟云学术

Irinotecan Dosing: Does the CPT in CPT-11 Stand for “Can’t Predict Toxicity”?

Published:2002-01-01 Issue:1 Volume:20 Page:7-8
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Ratain Mark J.¹

Affiliation:

1. Committee on Clinical Pharmacology, Cancer Research Center, The University of Chicago, Chicago, IL

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2002.20.1.7

Reference21 articles.

1. Phase I and pharmacokinetic trial of weekly CPT-11.

2. Bleiberg H, Cvitkovic E: Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: The European perspective. Eur J Cancer 32A: S18,1996-S23,

4. Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

5. Humerickhouse R, Lohrbach K, Li L, et al: Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 60: 1189,2000-1192,

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Individual Irinotecan Therapy Under the Guidance of Pre-Treated UGT1A1*6 Genotyping in Gastric Cancer;Technology in Cancer Research & Treatment;2024-01

2. Predictive Value of ABCC2 and UGT1A1 Polymorphisms on Irinotecan-Related Toxicities in Patients with Cancer;Genetic Testing and Molecular Biomarkers;2023-05-01

3. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose adjustment in gastric cancer treated with second-line chemotherapy;2022-09-06

4. Model‐Based Prediction of Irinotecan‐Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical Factors;Clinical Pharmacology & Therapeutics;2022-05-18

5. All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide;JCO Oncology Practice;2021-12-03